Valuation: Sanofi SA

Market Cap 90.11B 103B 83.18B 77.59B 146B 9,734B 149B 998B 387B 4,803B 387B 378B 16,734B P/E 2026 *
11.2x
P/E 2027 * 10.4x
Enterprise Value 101B 115B 92.85B 86.61B 163B 10,865B 166B 1,114B 432B 5,361B 432B 422B 18,678B EV / Sales 2026 *
2.14x
EV / Sales 2027 * 1.93x
Free-Float
89%
Yield 2026 *
5.67%
Yield 2027 * 6%
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-1.47% - - 103B
-2.48%+8.83%+54.68%+158.23% 1,097B
-1.76%+9.81%+66.64%+54.77% 622B
-1.05%+9.40%+38.03%+88.88% 449B
+0.83%+6.34%+29.51%+24.01% 334B
-1.38%+6.09%+37.91%+25.49% 294B
+0.30%+5.24%+31.61%+42.02% 286B
-0.10%+4.88%-28.09%-41.02% 213B
+0.44%+5.05%+30.67%+63.74% 195B
+0.01%+1.18%+14.16%+66.21% 157B
Average -0.51%+6.79%+30.57%+53.59% 405.19B
Weighted average by Cap. -1.09%+8.72%+41.34%+79.28%

Financials

2026 *2027 *
Net sales 47.09B 53.8B 43.47B 40.55B 76.41B 5,087B 77.77B 521B 202B 2,510B 202B 198B 8,746B 50.03B 57.16B 46.19B 43.08B 81.17B 5,405B 82.62B 554B 215B 2,667B 215B 210B 9,291B
Net income 8.15B 9.31B 7.52B 7.01B 13.21B 880B 13.45B 90.19B 35.01B 434B 34.96B 34.18B 1,513B 8.95B 10.23B 8.27B 7.71B 14.53B 967B 14.79B 99.15B 38.49B 477B 38.44B 37.58B 1,663B
Net Debt 10.47B 11.96B 9.66B 9.01B 16.98B 1,131B 17.29B 116B 44.99B 558B 44.93B 43.92B 1,944B 6.3B 7.2B 5.82B 5.43B 10.22B 681B 10.41B 69.77B 27.08B 336B 27.04B 26.44B 1,170B
Logo Sanofi SA
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-